Research study Program year 2021 Source: CMS Open Payments

Aveva Bpv15001

Research payments

$70,885

17 payments

Through program year 2021, $70,885 in research payments was reported against Aveva Bpv15001, across 17 payments, paid by Bard Peripheral Vascular, Inc..

Paid by: Bard Peripheral Vascular, Inc.
ClinicalTrials.gov: No trial number was reported for this study

By program year

2 rows

Year	Kind	Amount	Payments
2021	Research	$6,750	3
2019	Research	$64,135	14

Breakdown

Who paid Research payments · program years 2019–2021

Bard Peripheral Vascular, Inc. $70,885 17 payments

Who received the money Research payments · program years 2019–2021

Fresenius Medical C Organisation paid for research $14,326 1 payment
Sw Clinical Researc Organisation paid for research $12,400 1 payment
St Joseph Hospital Organisation paid for research $9,418 1 payment
Clinical Advancemen Organisation paid for research $8,826 1 payment
Tarrant Vascular Cl Organisation paid for research $5,250 1 payment
JML Research Associates Organisation paid for research $2,250 1 payment
Makris MD, LLC Organisation paid for research $2,250 1 payment
North Carolina Nephrology, PA Organisation paid for research $2,250 1 payment
Jacksonville Ctr Fo Organisation paid for research $2,150 1 payment
Akdhc Medical Resea Organisation paid for research $2,100 1 payment

Usually the institution or organisation running the study, not a person.

Records

Every payment, record by record

Date, amount, who was paid and what for — filter by year and kind, or download as CSV, free, in files of 5,000 rows.

Principal investigators named

10 shown

Named on the study's payments. Being named is not being paid: the money in the figures above went to the recipients listed, not necessarily to these people.

What you are looking at

Research payments are tied to a study. Being named on a study as a principal investigator is reported separately from being paid as a recipient, and the two are not the same thing — a named investigator has not necessarily received the money.